title: Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.
abstract: K2 or Spice is an emerging drug of abuse that contains synthetic cannabinoids, including JWH-018 and JWH-073. Recent reports indicate that monohydroxylated metabolites of JWH-018 and JWH-073 retain high affinity and activity at cannabinoid type-1 receptors (CB1Rs), potentially contributing to the enhanced toxicity of K2 compared to marijuana. Since the parent compounds also bind to cannabinoid type-2 receptors (CB2Rs), this study investigated the affinity and intrinsic activity of JWH-018, JWH-073 and several monohydroxylated metabolites at human CB2Rs (hCB2Rs). The affinity of cannabinoids for hCB2Rs was determined by competition binding studies employing CHO-hCB2 membranes. Intrinsic activity of compounds was assessed by G-protein activation and adenylyl cyclase (AC)-inhibition in CHO-hCB2 cells. JWH-073, JWH-018 and several of their human metabolites exhibit nanomolar affinity and act as potent agonists at hCB2Rs. Furthermore, a major omega hydroxyl metabolite of JWH-073 (JWH-073-M5) binds to CB2Rs with 10-fold less affinity than the parent molecule, but unexpectedly, is equipotent in regulating AC-activity when compared to the parent molecule. Finally, when compared to CP-55,940 and Δ(9)-tetrahydrocannabinol (Δ(9)-THC), JWH-018, JWH-018-M5 and JWH-073-M5 require significantly less CB2R occupancy to produce similar levels of AC-inhibition, indicating that these compounds may more efficiently couple CB2Rs to AC than the well characterized cannabinoid agonists examined. These results indicate that JWH-018, JWH-073 and several major human metabolites of these compounds exhibit high affinity and demonstrate distinctive signaling properties at CB2Rs. Therefore, future studies examining pharmacological and toxicological properties of synthetic cannabinoids present in K2 products should consider potential actions of these drugs at both CB1 and CB2Rs.
authors.affiliation: Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
authors.forename: Maheswari
authors.initials: M
authors.lastname: Rajasekaran
authors.forename: Lisa K
authors.initials: LK
authors.lastname: Brents
authors.forename: Lirit N
authors.initials: LN
authors.lastname: Franks
authors.forename: Jeffery H
authors.initials: JH
authors.lastname: Moran
authors.forename: Paul L
authors.initials: PL
authors.lastname: Prather
mesh_terms: D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D005786:Gene Expression Regulation; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000378:metabolism*; D015394:Molecular Structure; D009281:Naphthalenes / Q000737:chemistry / Q000378:metabolism*; D011485:Protein Binding; D011619:Psychotropic Drugs / Q000737:chemistry / Q000378:metabolism; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists / Q000235:genetics / Q000378:metabolism; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists* / Q000235:genetics / Q000378:metabolism*; D017450:Receptors, Opioid, mu / Q000235:genetics / Q000378:metabolism
chemical_list: D007211:Indoles; D009281:Naphthalenes; D011619:Psychotropic Drugs; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D017450:Receptors, Opioid, mu; C568258:JWH-073; C552597:1-pentyl-3-(1-naphthoyl)indole
references.citation: Toxicol Lett. 2010 Sep 1;197(3):157-62
references.pmid: 20566335
references.citation: Braz J Psychiatry. 2006 Jun;28(2):153-7
references.pmid: 16810401
references.citation: Br J Pharmacol. 2004 Mar;141(5):775-85
references.pmid: 14757702
references.citation: Infection. 2007 Dec;35(6):469-73
references.pmid: 17917699
references.citation: Forensic Sci Int. 2009 Oct 30;191(1-3):58-63
references.pmid: 19589652
references.citation: Eur J Biochem. 1995 Aug 15;232(1):54-61
references.pmid: 7556170
references.citation: Handb Exp Pharmacol. 2005;(168):53-79
references.pmid: 16596771
references.citation: Br J Pharmacol. 2008 Jan;153(2):319-34
references.pmid: 17994113
references.citation: Nat Neurosci. 2011 Jul 24;14(9):1160-6
references.pmid: 21785434
references.citation: J Leukoc Biol. 2003 Oct;74(4):486-96
references.pmid: 12960289
references.citation: Life Sci. 1990;46(22):1559-68
references.pmid: 2161974
references.citation: J Pharmacol Exp Ther. 2005 Nov;315(2):828-38
references.pmid: 16081674
references.citation: Przegl Lek. 2005;62(6):576-80
references.pmid: 16225128
references.citation: Pharmacol Rev. 2010 Dec;62(4):588-631
references.pmid: 21079038
references.citation: Eur J Pharmacol. 2011 Jun 1;659(2-3):139-45
references.pmid: 21333643
references.citation: J Neuroimmune Pharmacol. 2006 Mar;1(1):50-64
references.pmid: 18040791
references.citation: J Pharmacol Exp Ther. 2002 Aug;302(2):451-65
references.pmid: 12130702
references.citation: Mol Interv. 2011 Feb;11(1):36-51
references.pmid: 21441120
references.citation: Drug Alcohol Depend. 2000 Aug 1;60(2):133-40
references.pmid: 10940540
references.citation: Anal Chem. 2011 Aug 15;83(16):6381-8
references.pmid: 21740038
references.citation: Nat Med. 2012 Apr 05;18(4):504-5
references.pmid: 22481411
references.citation: PLoS One. 2011;6(7):e21917
references.pmid: 21755008
references.citation: Nature. 2005 Apr 7;434(7034):782-6
references.pmid: 15815632
references.citation: J Neurochem. 2007 Apr;101(1):87-98
references.pmid: 17241118
references.citation: Br J Pharmacol. 2004 Aug;142(8):1247-54
references.pmid: 15249429
references.citation: J Pharmacol Exp Ther. 1999 Nov;291(2):837-44
references.pmid: 10525107
references.citation: J Neurosci. 2003 Dec 3;23(35):11136-41
references.pmid: 14657172
references.citation: Biochem Pharmacol. 2012 Apr 1;83(7):952-61
references.pmid: 22266354
references.citation: Dtsch Arztebl Int. 2009 Jul;106(27):464-7
references.pmid: 19652769
references.citation: Br J Pharmacol. 2010 Jun;160(3):585-93
references.pmid: 20100276
references.citation: J Pharmacol Sci. 2004 Dec;96(4):362-6
references.pmid: 15599103
references.citation: PLoS One. 2012;7(1):e29900
references.pmid: 22291896
references.citation: Nat Rev Immunol. 2005 May;5(5):400-11
references.pmid: 15864274
references.citation: J Neurosci. 2005 Feb 23;25(8):1904-13
references.pmid: 15728830
references.citation: J Pharmacol Exp Ther. 2005 Aug;314(2):868-75
references.pmid: 15901805
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jul 2;38(1):4-15
references.pmid: 22421596
references.citation: PLoS One. 2008 Feb 20;3(2):e1640
references.pmid: 18286196
references.citation: Mini Rev Med Chem. 2008 Apr;8(4):370-87
references.pmid: 18473928
references.citation: Addiction. 2010 Oct;105(10):1859-60
references.pmid: 20840203
references.citation: Schizophr Res. 2010 May;118(1-3):309-10
references.pmid: 20056392
references.citation: J Mass Spectrom. 2009 May;44(5):832-7
references.pmid: 19189348
references.citation: Curr Med Chem. 2010;17(14):1393-410
references.pmid: 20166925
references.citation: Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
references.pmid: 4202581